Mesoblast announces a substantial holder change
A shareholder has become a substantial holder in Mesoblast as of July 31, 2026.
Stay informed with the latest news and media coverage for the biggest companies in Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place. Looking for another sector? Browse our industry database.
Last updated
A shareholder has become a substantial holder in Mesoblast as of July 31, 2026.
The facility provides funding for research and development activities.
The proposed biosimilar PB016 targets inflammatory bowel diseases like ulcerative colitis and Crohn's disease.
Revenue rose to ¥1.33 trillion, operating profit up 15.0%, and net profit up 24.3%, driven by Rexulti and other key products.
Unlock all announcements with a free trial
Otsuka Holdings Co. Ltd. (4578.TO) Japan Half-Year Ended June 30 GROUP 2026 2025 Revenue Y1.33 tln Y1.18 tln Operating Profit Y278.54 bln Y242.12 bln Pretax...
The expansion will boost production of Lilly's KwikPen injectable device, which is used to deliver diabetes and obesity medications Mounjaro and Zepbound.
While the projected loss would represent an improvement from the prior quarter’s loss of $3.40 per share, revenue is expected to plunge from the $389...
Hopes that the first drugs shown to slow Alzheimer’s disease could be rolled out on the NHS have risen after a second manufacturer entered price...
Unlock all articles with a free trial
Track Every Market Move
Follow your target companies and get daily news updates delivered straight to your inbox
Start for freeBrowse the top companies in Pharmaceuticals and stay on top of their latest developments.